Daily Sepsis Research Analysis
Analyzed 39 papers and selected 3 impactful papers.
Summary
Across today's sepsis-focused literature, a meta-analysis of 16 randomized trials shows no clinical benefit of intraoperative hemoadsorption during cardiopulmonary bypass, supporting de-implementation. A Japanese multicenter database study indicates early tracheostomy reduces mortality only in STeP high-risk septic patients. Methodologically, VDJ-REMIX enables biologically coherent immune repertoire modules that distinguish sepsis-specific signatures and correlate with severity.
Research Themes
- De-implementation evidence for intraoperative hemoadsorption
- Risk-stratified timing of tracheostomy in sepsis
- Network-based immune repertoire modular analysis for sepsis endotyping
Selected Articles
1. Efficacy of intraoperative hemoadsorption in patients undergoing cardiac surgery, a meta-analysis.
Across 16 RCTs (N=851), intraoperative hemoadsorption during cardiopulmonary bypass did not improve mortality or any major postoperative complications, including sepsis and septic shock. A small but significant decrease in albumin at ICU admission was observed in the hemoadsorption group.
Impact: This RCT-based synthesis provides decisive negative evidence against routine intraoperative hemoadsorption, informing de-implementation and resource stewardship.
Clinical Implications: Routine intraoperative hemoadsorption to prevent inflammatory or septic complications after cardiac surgery is not supported and may lower albumin; its use should be restricted to research or rigorously defined subgroups.
Key Findings
- Sixteen RCTs (N=851; HA 433 vs control 418) showed no reduction in 30-day/in-hospital mortality with intraoperative hemoadsorption.
- No significant differences were found for major complications, including atrial fibrillation, stroke, delirium, AKI/RRT, liver dysfunction, bleeding, pneumonia, sepsis, respiratory insufficiency, ventilation duration, septic shock, tamponade, ECMO, SOFA, plasma-free hemoglobin, or fibrinogen.
- Albumin at ICU admission was significantly lower in the hemoadsorption group.
Methodological Strengths
- Included only randomized controlled trials identified from multiple databases (PubMed, Scopus, Web of Science).
- Comprehensive assessment across numerous clinically meaningful outcomes with pooled analyses.
Limitations
- Heterogeneity in hemoadsorption devices, timing, and perioperative protocols may dilute subgroup effects.
- Risk-of-bias assessment and full PRISMA reporting are not detailed in the abstract; some data appear truncated.
Future Directions: Focus future RCTs on biomarker-defined hyperinflammatory phenotypes, standardize hemoadsorption protocols, and prioritize patient-centered outcomes and cost-effectiveness.
ObjectivesComparing clinical outcomes after cardiopulmonary bypass with hemodsorption (HA) versus cardiopulmonary bypass without HA in patients undergoing cardiac surgery in terms of mortality and major complications.MethodsPubMed, Scopus, and Web of Science databases were searched for relevant randomized control trials (RCTs) that compared postoperative clinical outcomes between patients receiving intraoperative HA with cardiopulmonary bypass versus patients receiving cardiopulmonary bypass without intraoperative HA in cardiac surgery.ResultsSixteen RCTs with 851 patients (433 in the HA group and 418 in the control group), were included in our meta-analysis. Our meta-analysis found no significant differences between the intraoperative HA group and the control group in patients undergoing cardiac surgery in terms of 30-days/in-hospital mortality, new-onset atrial fibrillation, stroke or cerebrovascular events, postoperative delirium, renal failure/acute kidney injury, need for renal replacement, postoperative liver dysfunction, thrombocytopenia, bleeding, volume of blood loss, pneumonia, sepsis, respiratory insufficiency, duration of postoperative ventilation, distributive/septic shock, pericardial tamponade, need for extracorporeal membrane oxygenation (ECMO) support, sequential organ failure assessment (SOFA) score at ICU admission, plasma-free hemoglobin levels, and fibrinogen levels. However, the pooled analysis showed a significant association between HA and decreased albumin at ICU admission (MD = - 0.28, 95% CI [0.55 to 0.01],
2. VDJ-REMIX: REpertoire Module Identification and eXploration.
VDJ-REMIX is an open-source, network-based framework that modularizes adaptive immune receptor repertoire data, addressing multicollinearity and missingness to yield biologically coherent signatures. In COVID-19 and non-COVID-19 sepsis cohorts, it separated disease-specific from shared severe-infection responses and identified modules correlated with severity, supporting biomarker discovery and mechanistic endotyping.
Impact: Provides a practical, validated methodology for dissecting complex immune repertoire patterns, enabling sepsis endotyping and biomarker development that standard techniques miss.
Clinical Implications: While not a diagnostic test yet, the tool can drive the creation of parsimonious repertoire-based biomarker panels to stratify sepsis patients by biology and severity, informing predictive enrichment in future trials.
Key Findings
- Introduces VDJ-REMIX, refactoring WGCNA into a tailored workflow (preprocessing, imputation, module detection) for AIRR data.
- In COVID-19 and non-COVID-19 sepsis, identified disease-specific versus shared severe-infection repertoire signatures and severity-correlated modules.
- Orthogonal validation via FCGR2B-genotype-sorted B cells and single-cell multi-omics linked BCR isotype/clonality to cytotoxic, IFN-responsive, and regulatory programs.
Methodological Strengths
- Validated across multiple disease contexts (autoimmunity, acute infections including sepsis) and data types, supporting generalizability.
- Network-based modular analysis mitigates multicollinearity and leverages imputation; open-source availability enables reproducibility.
Limitations
- Predominantly retrospective secondary analyses; no prospective clinical validation as a prognostic or diagnostic in sepsis.
- Computational complexity and need for domain expertise may limit immediate bedside deployment.
Future Directions: Apply VDJ-REMIX prospectively in ICU sepsis cohorts to derive parsimonious, clinically deployable repertoire panels; integrate with transcriptomic/proteomic signatures for pathway-guided trials.
MOTIVATION: High-throughput sequencing of B and T cell repertoires provides unprecedented insights into adaptive immunity but generates high-dimensional feature sets that are challenging to interpret. Standard dimensionality reduction techniques are often suboptimal for adaptive immune receptor repertoire (AIRR) data, which exhibits multi-collinearity, heterogeneous data types, and missingness. RESULTS: Here, we present VDJ-REMIX, an R package implementing a robust, network-based framework to deconstruct complex repertoire feature matrices into biologically interpretable modules. By refactoring weighted correlation network analysis (WGCNA), VDJ-REMIX provides a tailored workflow for preprocessing, imputation, and modularization of immune repertoire data. We demonstrate its utility across diverse contexts, including autoimmunity, inflammation, and acute infection. In autoimmune patients, VDJ-REMIX identified distinct B cell signatures that stratified diseases and revealed opposing dynamic responses to B cell-depleting versus anti-proliferative therapies. In COVID-19 and non-COVID-19 sepsis patients, it distinguished disease-specific signatures from shared severe infection responses and identified modules correlated with severity. Analysis of flow-sorted B cell populations stratified by FCGR2B genotype recapitulated known tolerance defects and uncovered population-specific repertoire signatures linked to inhibitory receptor dysfunction, providing orthogonal validation of module biological coherence. Finally, applied to a single-cell multi-omics dataset of immune cells in pancreatic ductal adenocarcinoma (PDAC) combining gene expression with AIRR-seq, VDJ-REMIX recovered modules linking BCR isotype usage and clonality to cytotoxic, interferon-responsive, and regulatory immune programmes. VDJ-REMIX is a versatile tool enabling systematic exploration of immunological variation and biomarker discovery from complex immune repertoire data. AVAILABILITY AND IMPLEMENTATION: VDJ-REMIX is freely available at https://github.com/Bashford-Rogers-lab/vdjremix.
3. Risk Stratification Using the Tracheostomy Early Prediction Score and the Association Between Early Tracheostomy and Mortality in Sepsis.
Using STeP-based risk stratification in a national ICU database, early tracheostomy (≤7 days) was associated with lower in-hospital mortality only in high-risk sepsis patients, with no benefit in low/moderate risk. Findings were robust across propensity matching and sensitivity analyses.
Impact: Clarifies a long-standing timing controversy by showing benefit only in a biologically high-risk stratum, enabling precision respiratory care decisions.
Clinical Implications: Consider early tracheostomy within 7 days for STeP high-risk septic patients while avoiding routine early tracheostomy in low/moderate risk; integrate STeP into airway strategy and trial design.
Key Findings
- Among high-risk (STeP ≥7) patients, early tracheostomy had lower in-hospital mortality versus late (28.0% vs 36.1%; OR 0.67, 95% CI 0.49–0.92).
- No mortality difference with early versus late tracheostomy in low- and moderate-risk strata.
- Results were consistent across generalized linear mixed-effects models and inverse probability weighting sensitivity analyses.
Methodological Strengths
- Large multicenter database with risk stratification and 1:1 propensity score matching within strata.
- Multiple sensitivity analyses including mixed-effects modeling and IPTW to address hospital-level variability and confounding.
Limitations
- Retrospective observational design with residual confounding and selection bias for tracheostomy timing.
- Generalizability outside the Japanese ICU context requires external validation.
Future Directions: Prospective, ideally randomized, trials targeting STeP high-risk patients to confirm causal benefit and refine optimal timing thresholds.
BACKGROUND: The impact of tracheostomy timing on mortality in mechanically ventilated patients is inconclusive, partly because identifying patients who require a tracheostomy is challenging. This study aimed to assess the association between tracheostomy timing and mortality using risk stratification based on the Sepsis Tracheostomy Early Prediction (STeP) score. METHODS: This retrospective cohort study used data from a Japanese Intensive Care Patient Database. Subjects with sepsis who required mechanical ventilation and underwent tracheostomy were included and classified into low- (0-2), moderate- (3-6), and high-risk (≥7) groups based on the STeP score. Early (≤7 d) and late (>7 d) tracheostomy were compared within each group using 1:1 propensity score matching (PSM). Sensitivity analyses were performed using a generalized linear mixed-effects model with hospitals as a random effect to account for between-hospital variability and the inverse probability of treatment weighting. The primary outcome was the in-hospital mortality rate. RESULTS: After 1:1 PSM matching, 52, 114, and 404 matched pairs were obtained in the low-, moderate-, and high-risk groups, respectively. In the high-risk group, early tracheostomy was associated with a significantly lower mortality rate than late tracheostomy (28.0% vs 36.1%; odds ratio, 0.67, 95% CI 0.49-0.92). No significant differences were observed between low- and moderate-risk groups. These findings were consistent across sensitivity analyses. CONCLUSIONS: Early tracheostomy was associated with lower mortality in high-risk subjects as identified by the STeP score, whereas no such association was observed in low- and moderate-risk patients.